We recently identified polymorphisms in Kaposi sarcoma-associated herpesvirus (KSHV)-encoded microRNA (miRNA) sequences from clinical subjects. Here, we examine whether any of these may contribute to KS risk in a European AIDS-KS case-control study.
in sub-Saharan Africa, iatrogenic KS resulting from immunosuppression regiments following organ transplantation, and epidemic or AIDS-associated KS. AIDS-KS represents the vast majority of KS cases worldwide, and much remains to be understood regarding the risk factors for KS in KSHV and human immunodeficiency virus (HIV)-coinfected subjects. The introduction of highly active antiretroviral therapy in developed countries has lead to a dramatic decrease in KS incidence among HIV-infected subjects [2, 3] . However, HIVinfected persons still have significantly increased risk of KS, and rates of KS have been stable in HIV-infected populations during the highly active antiretroviral therapy era. Recent reports of KS occurring in patients with high CD4 count and low or undetectable HIV loads emphasize the need for further insights into the correlates of KS in this population [4, 5] .
KSHV has an atypical worldwide prevalence and genotypic distribution. Most studies have failed to show any association between viral genotype and disease risk [6] [7] [8] . A recent report in Italy has suggested that KSHV genotype A predisposes patients with classical KS to a more rapid clinical disease pattern, correlated with higher viral loads, but the study was limited in size [9] .
Recently, the discoveries of microRNAs (miRNAs) in large double-stranded DNA viruses, including herpesviruses, have presented another layer of complexity in understanding KSHV pathogenesis [10] [11] [12] . MiRNAs are small noncoding RNAs, typically 19-22 nt in length, that posttranscriptionally regulate gene expression by recognizing and binding to specific targets in the 3 untranslated regions of mRNAs, resulting in either down-regulation or degradation of the target messenger RNA. KSHV encodes 12 distinct pre-miRNAs resulting in 17 mature miRNAs, all located within the latency-associated region that is highly expressed in all KSHV-associated malignancies. A cluster of 10 viral pre-miRNAs are encoded by a 2.8-kb intragenic region located between the viral FLIP and kaposin genes. The remaining 2 pre-miRNAs are found within the K12 open reading frame [11] .
Cellular miRNAs have been linked to many processes, including proliferation, differentiation, and apoptosis. Few targets of virally encoded miRNAs are known, but it is likely they play key roles in latency, immune evasion, and pathogenesis. We recently demonstrated that the KSHV-encoded miRNA region is highly conserved in KSHV cell lines and clinical samples from patients with KS and multicentric Castleman disease [13] . However, we observed a distinct cluster of sequences that differed phylogenetically in the miRNA region. Moreover, single nucleotide polymorphisms (SNPs) were observed in some premiRNA sequences, one of which has been shown to affect processing of the miRNAs by Drosha and consequently affect mature transcript expression levels.
We recently reported a study of risk factors for KS in HIVinfected subjects [14] . In this study, we analyzed KSHV load detection in peripheral blood mononuclear cells and examined miRNA sequences from KSHV-infected case patients and controls to determine whether any specific polymorphisms correlate with KS risk.
PATIENTS, MATERIALS, AND METHODS
Patient samples. The samples were collected in 1993 through a collaboration of researchers in European countries, and the project was funded by the European Union European Study on HIV-Associated Kaposi's Sarcoma (EURO-SHAKS). The study design included HIV-positive, KS-positive case patients matched with 2 HIV-positive patients who either had low CD4 cell counts (!200 cells/mL) or another AIDS-defining illness. Informed consent and detailed questionnaire data were collected from each study participant. Participants residing in Spain were followed biyearly until 2004. Analysis of serological data from this study has been reported elsewhere [14] . Peripheral blood samples were collected for each patient, and DNA was extracted [15] . Ethical approval was obtained from the National Cancer Institute Institutional Review Board and the ethics review boards at participating sites.
Real-time polymerase chain reaction (PCR) KSHV load quantification. A standard input of ∼200 ng per PCR reaction was used when possible. Samples with lower concentrations were run at the maximum volume input of 10 mL. KSHV load was determined using a quantitative real-time PCR assay which specifically targets the K6 gene region [16, 17] . A second realtime assay for human endogenous retrovirus 3 (ERV-3), present at 2 copies per genomic cell, was used to quantify cellular DNA [18] . For each real-time PCR assay, each sample was assayed in triplicate, and a mean of the 3 individual reactions was used to determine target copy number. KSHV load was then calculated as copies per million cells.
Samples were designated qualitative positive if the estimated mean viral copy number was !1 or if there was no amplification in any of the triplicate reactions. Quantitative estimates for these samples were not determined because target amplification occurred at the lower limit of assay sensitivity. Samples that fell into this category were retested to confirm the findings.
Amplification of KSHV miRNA and K1 gene regions. Amplification of each gene region was performed using a nested PCR strategy with Jumpstart Readymix (Sigma) as described elsewhere [19] . Three overlapping PCR amplifications were performed for the miRNA cluster region. The overlapping sequences included a 1065-bp fragment containing miRNAs 1-5, a 1014-bp fragment encoding miRNAs 6, 11, and 7; and a 1266-bp fragment encoding miRNAs 7-9. The nested PCR primers used to amplify the individual fragments are listed in Table 1 , and the positions are shown in Figure 1 .
DNA from case patients with KS and controls were grouped separately for nested PCR testing. In addition, samples with estimated viral copies per million cell equivalents 11000 were segregated from samples with lower copy numbers to reduce the chance of cross-contamination. Universal standards were employed to prevent nonspecific or cross-contamination of samples, including using separate rooms for reagent preparation, first-and second-round assay plate setup, and gel analysis. All equipment, including pipettes and hoods, were cleaned with bleach and/or ultraviolet irradiated before and after each assay. A checkerboard plate setup was used so that no sample was directly beside another either horizontally or vertically. Molecular grade water was used for no-template controls, and they were included in every row of the 96-well plates used for amplification. Samples were retested if any control wells showed evidence of nonspecific amplification.
Cloning and sequencing of KSHV miRNA and K1 gene regions. The PCR products from the second-round nested Table 1 .
reactions were electrophoresed on 1.5% agarose gels, and bands of the expected size were excised. DNA was extracted using QiaQuick (Qiagen), and 5 mL was used in a confirmatory gel to verify size and obtain an estimate of DNA concentration. Products with low concentrations were cloned using the pGEM T-Easy vector system (Promega). Otherwise, all products were sequenced directly, using the amplification primers as sequencing primers, by an ABI Prism 3130xl sequence detector system (Applied Biosystems). The sequence information was assembled using data from both forward and reverse overlapping sequences for the K1, T0.7, and 3 individual miRNA cluster region fragments. The entire miRNA cluster region was assembled using 3 overlapping sequences as shown in Figure 1 [13] .
Phylogenetic analysis. DNA sequences obtained in this study were aligned using CLUSTAL X (version 1.81) with relevant reference sequences, available from the GenBank database, representing all known subtypes for the genes analyzed. Alignments were made using the nucleotide sequences, with the exception of the K1 gene, which was translated into amino acid sequences prior to alignment. The CLUSTAL X files were converted into Mega formats (version 2.1) for neighbor-joining analysis and phylogenetic tree generation using the Kimura 2-parameter evolutionary model. Statistical analysis. Viral load DNA distributions were compared using analysis of variance. Odds ratios (ORs) of detecting a SNP were calculated independently for each SNP with sue of Cornfields' method for computing confidence intervals (CIs). Correction for data sparsity and incomplete tables was attempted by adding a small constant to all cells [20] . All analyses were performed using STATA, version 10.1 (StataCorp).
RESULTS

KSHV load detection in peripheral blood mononuclear cells.
DNA was available from 398 subjects for screening with realtime quantitative PCR to determine viral load. Of these, 157 samples failed to meet the optimum DNA concentration requirement of 200-250 ng per 10 mL. These samples were still included in the study because the primary purpose of the viral load testing was to identify samples for genotyping. The rate of detection of KSHV DNA did not differ significantly between the samples with optimal and suboptimal DNA concentrations (detection rates, 21.6% and 19.9%, respectively), and therefore, all samples were included in subsequent analyses.
Case patients with KS were more likely to be positive for KSHV DNA (50.7%) than were controls (6.8%), consistent with other reports (OR, 14.08 [95% CI, 7.6-26.8]) [21] . KSHV load estimates in subjects with positive test results also tended to be Figure   6 1 ϫ 10 n p 16 2. Five KS case samples were qualitatively positive by PCR. Additionally, 5 samples from KSHV antibody-negative subjects (6.2%) were weakly positive by PCR (1-5 raw copies; viral load, 42-235 copies/ cells). 6 1 ϫ 10 Phylogenetic analyses and subtype determination. All KSHV strains analyzed from study subjects were subtype A or C on the basis of K1 amino acid analysis. K1 subtypes were determined for 19 of 21 cases, of which 13 were designated subtype C (68.4%). Ten (70%) of the 13 control subject K1 sequences were also subtype C. Similarly, for T0.7, most subjects were subtype C (20 [74%] of 27), and sequences were very similar. More variation was observed in the 7 A subtype sequences, 6 of which were from case patients with KS. Phylogenetic analysis of the miRNA cluster region resulted in a tree with similar topology to that we reported elsewhere [13] . KSHV subtype information is shown in Table 2 . Phylogenetic trees are available on request.
Conservation of KSHV-encoded miRNAs in cases and controls. Within the 1065-bp fragment encoding KSHV-mir-K12 1-5, the conservation was 93.7%. The 1014-bp fragment encoding KSHV mir-K12 6, 11, and 7 was the most conserved (94.3%), whereas the least conserved (90.8%) was the 1229-bp fragment encoding KSHV mir-K12 7-9. The lower conservation for the mirK12 7-9 portion of the cluster region is a consequence of multiple polymorphisms located in the sequence between mir-K12 8 and 9, including the very polymorphic mir-K12 9. A detailed analysis of SNPs detected in the KSHV miRNA cluster region and the K12/T0.7 gene are shown in Figures 3 and 4 . Detection of pre-miRNA polymorphisms. Consistent with our findings reported elsewhere [13] , polymorphisms within pre-miRNA regions were rare overall with 6 miRNAs, namely KSHV-mir-K12 1, 6, 8, 10, 11, and 12, showing complete conservation in the current study. Polymorphisms within the seed region, nucleotides 2-8 in the mature miRNA, were even rarer, with complete conservation observed in 27 of 29 study subjects. However, 1 study subject, Bar0049, had 3 SNPs in the seed region of KSHV mir-K12 9, previously reported in the BCP-1 cell line. An insertion was found in the seed region sequence of KSHV mir-K12 3 from Bar0080, a case patient with KS.
We disregarded polymorphisms present in only a single sequence because they may be attributable to PCR artifacts. Such SNPs were found in KSHV mir-K12 2, 3, 4, and 9. However, it should be noted that many SNPs discovered in single sequences in our initial report have been verified in the current study because of the expanding number of sequences available for analysis.
We have reported polymorphisms in KSHV mir-K12 4, 6, 7, 8, and 9 elsewhere [13] . Many of these polymorphisms were observed in at least 1 of the sequences in the current study. An additional polymorphism was identified in the mature transcript sequence of KSHV-mir-K12 2 from one case patient and one control. Detailed representation of polymorphisms occurring in the KS case and control samples are shown in Figures  3 and 4 . The mapping of SNPs, insertions, and deletions in the current study suggests that the changes are more common in case patients with KS than controls.
Polymorphisms outside pre-miRNA sequences. Recent studies have shown that polymorphisms in primary miRNAs are important determinants of Dicer and Drosha processing, which affects mature miRNA generation [22, 23] . We therefore examined the sequence outside the pre-miRNA-coding region for additional polymorphisms. We found 52 polymorphisms outside the pre-miRNAs in the cluster region and 15 in the T0.7 amplicon analyzed. Polymorphisms occurring within a few base pairs of the start of pre-miRNA sequences were noted for mir-K12 3, 5, and 6. The region between KSHV-mir-K12 8 and 9 is highly variable to a degree unexpected for a herpesvirus. Polymorphisms preceding KSHV-mir-K12 1 and 10 and preceding 9 and 12 are not included in our analysis because they are external to the region sequenced. The distribution of polymorphisms in the miRNA cluster region is illustrated in Figures  3, and Figure 4 illustrates the distribution of polymorphisms in the T0.7 region.
Disease association of polymorphisms. Figure 5 shows the OR for detecting a SNP in case patients with KS versus controls for both the T0.7 and miRNA cluster region. Because amplification and cloning of the regions was possible in 29 or fewer subjects, the standard error for any OR estimate is expected to be large. Thus, the study has a limited power to detect even a large effect size (70% for the largest observed) if type I error is set at 5%. In other words, all observations are bound to not be statistically significant at the conventional .05 level. Nevertheless, it is possible to observe that polymorphisms in miRNAs 4, 5, 7, and 9 were strikingly more common in case patients than in controls. Several others outside of pre-miRNAs, especially in the T0.7 amplicon, were similarly more common in case patients, whereas most were seen only slightly more frequently in case patients than controls or at similar rates in the 2 groups.
DISCUSSION
We have previously reported sequence analysis of the KSHV miRNA-encoding regions from PEL cells lines and clinical subjects that demonstrated 2 major phylogenetic groups consisting of a large number of very conserved A and C sequences and a second smaller group of more diverse sequences designated B/Q [13] . We also previously reported SNPs within the premiRNA sequences of several of the KSHV-encoded miRNAs, at least one of which has been demonstrated to affect miRNA processing and, hence, expression levels [13, 24] . Studies to determine the effect of other SNPs on miRNA processing and expression are warranted.
Here we report the analysis of sequences of the KSHV miRNA-encoding regions in the context of an AIDS-KS casecontrol study, to examine the possibility that polymorphisms in miRNA-encoding regions may be associated with KS risk. We have shown that polymorphisms in miRNAs 4 and 5 are more common in case patients with KS than in controls, although this could not reach statistical significance because of the limited sample size of our study. These findings are highly suggestive of an important role for KSHV-encoded miRNAs in KS pathogenesis and that some viruses may have evolved to be less pathogenic by modulating the expression of the miRNAs they encode. In addition, we have for the first time, to our knowledge, identified polymorphisms in the KSHV-encoded primary miRNA sequences. Because polymorphisms in primary miRNA sequences have been shown to affect miRNA processing and maturation [22, 23] , we suspect that at least some of these may have effects on the expression levels of KSHV-encoded miRNAs in infected cells, which is in concordance with the fact that some of them also occur more frequently in case patients than in controls.
Several polymorphisms observed in the T0.7 region were more common in case patients than in controls. However, the K12 gene has also been reported to be a target for cellular immune responses [25] . Two of the nonsynonymous polymorphisms we observed (at nucleotides 119,955 and 118,037) were within reported cytotoxic T lymphocyte epitopes [26, 27] . This raises the intriguing possibility that cytotoxic T lymphocyte escape may drive changes in the miRNA-encoding sequences, affecting miRNA expression, which may result in changes in pathogenesis. The increasingly significant preponderance of polymorphisms in case patients with KS suggests that the changes observed may actually serve to promote KSHV pathogenesis and the development of cancer. It was recently reported that mir-K12 7 is involved in the induction of interleukin 6 and 10 secretion by macrophages and monocytes, modulating immune responses to KSHV tumor progression [28] . Also, recent findings indicate that mi-K12 9 targets KSHV open reading frame 50, which functions as the switch between latency and lytic viral replication [29] . We had initially hypothesized that miRNAs that were highly conserved would be more likely to play critical roles in the KSHV life cycle; however, these recent reports are more suggestive of an important role for the miRNAs in which SNPs occur, increasing the significance of our findings.
Other studies have attempted to find an association between KSHV sequence variation and KS risk but have failed to do so, finding instead that sequence variation, especially in the K1 gene, is associated with ethnicity and geographical variations. [6] [7] [8] . Consequently, the SNPs we report here may represent the first "virulence factors" to be discovered for KSHV.
Our study has some limitations. The study design was crosssectional, and subjects were recruited during the era before highly active antiretroviral therapy. Consequently, we cannot be sure that some subjects included as controls may not have developed KS at a later date or would have done so if they had not succumbed to another AIDS-associated illness. DNA was not available for all subjects or was limited, which affected our ability to amplify the gene regions of interest for sequencing. In addition, the viral load tended to be higher in case patients than in controls; therefore, amplification of the large amplicons we used in this study was more successful for case patients. Obviously, we were only able to examine sequences from subjects with detectable viral DNA, which limited the sample size and, consequently, the power of the study. Nevertheless, we feel our study has added substantially to the available body of evidence on the possible pathogenic role of SNPs related to KSHV miRNA. In particular, our study points to individual SNPs for which in vitro studies may be warranted to elucidate possible effects on miRNA activity.
In conclusion, we have extended our observations of variation in the miRNA-encoding regions of KSHV in clinical subjects by examining sequences from subjects of an AIDS-KS casecontrol study. We have reported for the first time SNPs in the primary miRNA sequences of KSHV that may have additional effects on miRNA processing and expression. Sequence differences observed in this and our other studies may have consequences for disease risk and pathogenesis, and we suggest that this is an area which merits further study.
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